First quarter shows Teva on track to make 2017 woes history

3 May 2018

In his first full quarterly results statement since taking the helm at Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), Danish chief executive Kåre Schultz heralded “a solid start,” to the firm’s deep restructuring program, noting the company is “on track to meet our cost reduction targets of $1.5 billion in 2018 and $3 billion by the end of 2019.”

Investors reacted warmly to the results, which show the firm took in sales of $5.1 billion, down 10% from 2017, but well ahead of the Financial Times’ consensus view of $4.8 billion.

Following Generally Accepted Accounting Principles (GAAP), profit was $2.3 billion, down 17% from the same period last year. The earnings per share figure was $1.03.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK